Venmax Drugs and Pharmaceuticals Ltd
Allotment of 28,00,000 Convertible warrants in to Equity shares on preferential basis and pursuant to Regulation 30 read with Schedule III of SEBI LODR Regulations, 2015
FUNDRAISE
▲ Positive Development
MEDIUM RISK
📅 Filed on BSE: 23 Mar 2026, 03:53 PM IST · BSE ID: 1639cd07-8b9e-4ba2-a625-7a835c3d2275
View Original BSE Filing (PDF)
💡
In Simple Terms
Two investors converted their warrants into 28 lakh equity shares, paying Rs. 4.20 Crore, increasing the company's share capital.
🤖 AI Summary
- 28,00,000 equity shares allotted on conversion of equal warrants; Rs. 4,20,00,000 cash received
- Two non-promoter warrant holders exercised conversion rights on March 23, 2026
- Issue price Rs. 20/- per share; face value Rs. 10/-; premium Rs. 10/- each
- Paid-up capital now Rs. 11,58,29,300/-; total shares outstanding 1,15,82,930
- 36,81,000 fully convertible warrants remain outstanding from original 1,00,25,000 allotted
🔢 Key Numbers — exact figures from BSE filing, not rounded
Equity shares allotted
28,00,000 shares
Cash received from warrant conversion
Rs. 4,20,00,000/-
Issue price per share
Rs. 20/-
Post-allotment paid-up capital
Rs. 11,58,29,300/-
Total equity shares outstanding
1,15,82,930 shares
Outstanding convertible warrants remaining
36,81,000 warrants
🏢 How This Affects the Company
Company received Rs. 4,20,00,000/- cash inflow from exercise price. Paid-up capital increased from Rs. 10,38,29,300/- to Rs. 11,58,29,300/-. Equity share count rose by 28,00,000 shares.
Dilution of 2.42% to existing shareholders through allotment of 28,00,000 shares. Outstanding warrants of 36,81,000 create future dilution if exercised.
👥 What This Means For Shareholders
✅
Action Required
Existing shareholders should review shareholding dilution impact; 28,00,000 shares allotted represents approximately 2.42% dilution to current shareholding structure.
👤
Who Is Affected
All existing shareholders experience voting power dilution. Two non-promoter warrant holders — Jugal Kishore Bhagat and Pushpa Bhaju — converted 13,00,000 and 15,00,000 warrants respectively into equity stakes.
🔍
Management Signal
Management executed warrant conversion process as contractually obligated; capital structure management demonstrates orderly execution of agreed warrant terms with non-promoter investors.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Filing of Reg 30/31 updates when remaining 36,81,000 warrants are exercised or expire
Q4 FY26 financial results — verify cash impact of Rs. 4.20 Cr reflected in balance sheet
Promoter shareholding change disclosures — track impact of warrant conversion on shareholding patterns
MEDIUM RISK
Outstanding warrants of 36,81,000 create material future dilution risk. Warrant expiry dates and conversion terms not fully disclosed in filing.
💡 Investor Takeaway
Venmax Drugs allotted 28,00,000 equity shares from warrant conversion on March 23, 2026, collecting Rs. 4,20,00,000/- in exercise price. Paid-up capital now Rs. 11,58,29,300/-. Of original 1,00,25,000 warrants, 36,81,000 remain convertible, creating future dilution exposure for existing shareholders.
⚖️ Strengths & Concerns
✅ Positives
- Immediate cash realization of Rs. 4,20,00,000/- at Rs. 15/- per warrant exercise price demonstrates investor confidence
- Clear warrant conversion mechanism established with specific investors and share count — transparent capital structure management
⚠️ Concerns
- 36,81,000 fully convertible warrants remain outstanding; future conversion creates ongoing dilution risk to shareholders
- Warrant allotment details lack disclosure of allotment date, warrant expiry date, and full terms of original warrant agreement
📅 Company Track Record
Company incorporated in 1988 (CIN: L24230TG1988PLC009102). This is first BSE filing captured in ForgeUp records. Original warrant allotment occurred on March 20, 2025; conversion execution completed March 23, 2026 — one year after initial allotment.
Based on publicly available historical data. For context only.